Agents and Actions

, Volume 33, Issue 1–2, pp 197–199 | Cite as

Vascular responses to histamine at low temperatures in normal digital skin and Raynaud's phenomenon

  • C. B. Bunker
  • J. C. Foreman
  • P. M. Dowd
Histamine and Clinical Studies


A defective histaminergic dilating system in the digital vasculature has been proposed for the pathophysiology of Raynaud's phenomenon but this is not supported by studies of digital intradermal responses to histamine or agents which cause histamine release. The vascular responses (measured by planimetry and laser Doppler flowmetry) of digital skin over the middle phalanx to intradermal histamine, compound 48/80 and Substance P have now been studied at low temperatures (because it is in the cold that Raynaud's phenomenon occurs) in normal controls and patients with primary Raynaud's phenomenon. A cold-related attenuation of mast cell histamine release by compound 48/80 was observed in both normal and Raynaud's subjects. These results do not support a major histaminergic defect in the pathogenesis of Raynaud's phenomenon.


Mast Cell Histamine Normal Control Histamine Release Vascular Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    P. M. Dowd,The treatment of Raynaud's phenomenon. Br. J. Dermat.114, 527–533 (1986).Google Scholar
  2. [2]
    K. Lafferty, V. C. Roberts, J. C. de Trafford and L. T. Cotton,On the nature of Raynaud's phenomenon: the role of histamine. Lancetii, 313–315 (1983).Google Scholar
  3. [3]
    C. B. Bunker, J. C. Foreman and P. M. Dowd,Digital vascular responses to histamine, compound 48/80 and calciton in gene-related peptide in patients with Raynaud's phenomenon. J. Invest. Dermatol. in press (1991).Google Scholar
  4. [4]
    E. V. Allen and G. E. Brown,Raynaud's disease: a critical review of the minimum requisites for diagnosis. Am. J. Med. Sci.183, 187–200 (1932).Google Scholar
  5. [5]
    C. B. Bunker and S. W. Lanigan, M. H. A. Rustin and P. M. Dowd,The effects of topically applied hexyl nicotinate on the cutaneous blood flow in patients with Raynaud's phenomenon. Br. J. Dermatol.119, 771–776 (1988).PubMedGoogle Scholar
  6. [6]
    S. D. Brain, and T. J. Williams,Substance P regulates the vasodilator activity of calcitonin gene-related peptide. Nature335, 73–75 (1988).PubMedGoogle Scholar
  7. [7]
    M. Raynaud,On local asphyxia and symmetrical gangrene of the extremities. InSelected monographs. 121 (Trans. T. Barlow). New Sydenham Society, London 1888.Google Scholar
  8. [8]
    T. Lewis and G. W. Pickering,Observations upon maladies in which the blood supply to digits ceases intermittently or permanently, and upon bilateral gangrene of digits; observations relevant to so-called “Raynaud's disease”. Clin. Sci.1, 327–366 (1933).Google Scholar
  9. [9]
    J. C. Foreman,Histamine, histamine antagonists and cromones. InHandbook of Experimental Pharmacology, 87/1, pp. 289–308. (Eds. M. W. Greaves and S. Schuster. Springer-Verlag, Berlin, Heidelberg, New York 1989.Google Scholar

Copyright information

© Birkhäuser Verlag 1991

Authors and Affiliations

  • C. B. Bunker
    • 1
  • J. C. Foreman
    • 2
  • P. M. Dowd
    • 1
  1. 1.Department of DermatologyThe Middlesex HospitalLondonUK
  2. 2.Department of Pharmacology, University College and Middlesex School of MedicineUniversity CollegeLondonUK

Personalised recommendations